Latest On Mitsubishi Tanabe Pharma Corporation (MTZXF):
About Mitsubishi Tanabe Pharma Corporation (MTZXF):
Mitsubishi Tanabe Pharma Corporation manufactures and sells pharmaceuticals in Japan, Europe, North America, other Asian countries, and internationally. The company primarily offers drugs for immuno-inflammation, diabetes and kidney, and central nervous system diseases; vaccines; and OTC products. It offers Simponi, a treatment agent for rheumatoid arthritis (RA); Canalia, Invokana, Tenelia, and Canaglu, treatment agents for type 2 diabetes mellitus; Stelara and Amiselimod for treatment of Crohn's disease; Radicava, an amyotrophic lateral sclerosis (ALS) treatment agent; Gilenya, a treatment agent for multiple sclerosis; and Remicade for treatment of RA, Crohn's disease, and various inflammatory autoimmune diseases. The company also provides Lexapro, an anti-depressant agent; Imusera for multiple sclerosis; Rupafin, an oral allergy treatment agent; Talion, an anti-allergic agent; Fasinumab, a human anti-NGF monoclonal antibody; Dersimelagon for immnuno-inflammation; Vadadustat, for treatment of renal anemia; and Apararenone, for treatment of non-alcoholic steatohepatitis. In addition, it offers vaccines, such as influenza vaccine, Tetrabik, Mearubik, Varicella vaccine, and JEBIK V. The company has collaborations with Dyadic International, Inc.; Hitachi Ltd.; HitGen Ltd.; and Viela Bio, Inc. The company was founded in 1678 and is headquartered in Osaka, Japan. Mitsubishi Tanabe Pharma Corporation is a subsidiary of Mitsubishi Chemical Holdings Corporation.
General
- Name Mitsubishi Tanabe Pharma Corporation
- Symbol MTZXF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorOther
- IndustryOther
- Full Time Employees 7,228
- Fiscal Year EndMarch
- Web URLhttp://www.mt-pharma.co.jp
Valuation
- Trailing PE 79.6
- Forward PE 204.08
- Price/Sales (Trailing 12 Mt.) 2.88
- Price/Book (Most Recent Quarter) 1.28
- Enterprise Value Revenue 0.02
- Enterprise Value EBITDA 0.21
Financials
- Most Recent Quarter 0000-00-00
- Revenue Per Share $0
- Gross Profit 244.12 billion
- Quarterly Earnings Growth 0%
ESG Rating
Highlights
- Market Capitalization 10.15 billion
- PEG Ratio -43116.6
Share Statistics
- % Held by Insiders <1%
Technicals
- 50 Day Moving Average 18.08
- 200 Day Moving Average 15.1
Dividends
- Dividend Date 2018-06-25
- ExDividend Date N/A
- Dividend Per Share $0.51
Mitsubishi Tanabe Pharma Corporation (MTZXF) Dividend Calendar:
MTZXF's last dividend payment was made to shareholders on June 25, 2018.
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
Mitsubishi Tanabe Pharma Corporation (MTZXF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2018-12-31 | 2018-12-31 | $1.12 billion | $0.26 | ||
2018-09-30 | 2018-09-30 | $916.03 million | $0.18 | ||
2018-06-30 | 2018-06-30 | $950.01 million | $0.23 | ||
2018-03-31 | 2018-03-31 | $892.79 million | $0.10 | $0.17 | -43.29% |
2017-12-31 | 2017-12-31 | $1.12 billion | $0.35 | $0.37 | -4.89% |
2017-09-30 | 2017-09-30 | $936.89 million | $0.21 | $0.26 | -20.62% |
2017-06-30 | 2017-06-30 | $958.43 million | $0.27 | $0.25 | 8.96% |
2017-03-31 | 2017-03-31 | $894.34 million | $0.17 | ||
2016-12-31 | 2016-12-31 | $120.24 billion | $0.39 | ||
2016-09-30 | 2016-09-30 | $0.25 | $0.23 | 9% | |
2016-06-30 | 2016-06-30 | $0.36 | |||
2016-03-31 | 2016-03-31 | -$0.06 | |||
2015-12-31 | 2015-12-31 | $0.45 | |||
2015-09-30 | 2015-09-30 | $0.21 | |||
2015-06-30 | 2015-06-30 | $0.22 | |||
2015-03-31 | 2015-03-31 | -$0.13 | |||
2014-12-31 | 2014-12-31 | $0.25 | |||
2014-09-30 | 2014-09-30 | $0.39 | |||
2014-06-30 | 2014-06-30 | $0.17 | |||
2014-03-31 | 2014-03-31 | $0.03 | |||
2013-12-31 | 2013-12-31 | $0.27 | |||
2013-09-30 | 2013-09-30 | $0.33 | |||
2013-06-30 | 2013-06-30 | $0.19 | |||
2013-03-31 | 2013-03-31 | $0.13 | |||
2012-12-31 | 2012-12-31 | $0.35 | |||
2012-09-30 | 2012-09-30 | $0.20 | |||
2012-06-30 | 2012-06-30 | $0.24 | |||
2012-03-31 | 2012-03-31 | $0.07 | |||
2011-12-31 | 2011-12-31 | $0.37 | |||
2011-09-30 | 2011-09-30 | $0.20 | |||
2011-06-30 | 2011-06-30 | $0.25 | |||
2011-03-31 | 2011-03-31 | -$0.03 | |||
2010-12-31 | 2010-12-31 | $0.36 | |||
2010-09-30 | 2010-09-30 | $0.17 | |||
2010-06-30 | 2010-06-30 | $0.28 | |||
2010-03-31 | 2010-03-31 | -$0.05 | |||
2009-12-31 | 2009-12-31 | $0.38 | |||
2009-09-30 | 2009-09-30 | $0.04 | |||
2009-06-30 | 2009-06-30 | $0.21 |
Mitsubishi Tanabe Pharma Corporation (MTZXF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date |
---|
Research Development |
Income Before Tax |
Selling General Administrative |
Gross Profit |
Ebit |
Operating Income |
Income Tax Expense |
Total Revenue |
Cost of Revenue |
Total Other Income Expense Net |
Net Income From Continuing Operations |
Net Income Applicable to Common Shares |
Cash Flow:
Date |
---|
Investments |
Change to Liabilities |
Total Cash Flow from Investing Activities |
Net Borrowings |
Total Cash Flow from Financial Activities |
Change to Operating Activities |
Change in Cash |
Total Cash from Operating Activities |
Depreciation |
Other Cash Flow from Investing Activities |
Change to Inventory |
Change to Account Receivables |
Other Cash Flow from Financing Activities |
Change to Net Income |
Capital Expenditures |
Balance Sheet:
Date |
---|
Total Liabailities |
Total Stockholder Equity |
Other Current Liabilities |
Total Assets |
Common Stock |
Other Current Assets |
Retained Earnings |
Other Liabilities |
Other Assets |
Cash |
Total Current Liabilities |
Other Stockholder Equity |
Property, Plant & Equipment |
Total Current Assets |
Long Term Investments |
Net Tangible Assets |
Short Term Investments |
Long Term Debt |
Inventory |
Accounts Payable |
Mitsubishi Tanabe Pharma Corporation (MTZXF) Chart:
Mitsubishi Tanabe Pharma Corporation (MTZXF) News:
Below you will find a list of latest news for Mitsubishi Tanabe Pharma Corporation (MTZXF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Mitsubishi Tanabe Pharma Corporation (MTZXF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|
Mitsubishi Tanabe Pharma Corporation (MTZXF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|